328 related articles for article (PubMed ID: 30589984)
1. The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial.
Thomas D; Farrell M; McRobbie H; Tutka P; Petrie D; West R; Siahpush M; Gartner C; Walker N; Mendelsohn CP; Hall W; Paul C; Zwar N; Ferguson SG; Boland VC; Richmond R; Doran CM; Shakeshaft A; Mattick RP; Courtney RJ
Addiction; 2019 May; 114(5):923-933. PubMed ID: 30589984
[TBL] [Abstract][Full Text] [Related]
2. Cytisine versus varenicline for smoking cessation for Māori (the indigenous people of New Zealand) and their extended family: protocol for a randomized non-inferiority trial.
Walker N; Smith B; Barnes J; Verbiest M; Kurdziel T; Parag V; Pokhrel S; Bullen C
Addiction; 2019 Feb; 114(2):344-352. PubMed ID: 30276931
[TBL] [Abstract][Full Text] [Related]
3. Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial.
Courtney RJ; McRobbie H; Tutka P; Weaver NA; Petrie D; Mendelsohn CP; Shakeshaft A; Talukder S; Macdonald C; Thomas D; Kwan BCH; Walker N; Gartner C; Mattick RP; Paul C; Ferguson SG; Zwar NA; Richmond RL; Doran CM; Boland VC; Hall W; West R; Farrell M
JAMA; 2021 Jul; 326(1):56-64. PubMed ID: 34228066
[TBL] [Abstract][Full Text] [Related]
4. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
Leaviss J; Sullivan W; Ren S; Everson-Hock E; Stevenson M; Stevens JW; Strong M; Cantrell A
Health Technol Assess; 2014 May; 18(33):1-120. PubMed ID: 24831822
[TBL] [Abstract][Full Text] [Related]
5. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
[TBL] [Abstract][Full Text] [Related]
6. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
[TBL] [Abstract][Full Text] [Related]
7. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Lindson-Hawley N; Thomas KH; Fanshawe TR; Lancaster T
Cochrane Database Syst Rev; 2016 May; 2016(5):CD006103. PubMed ID: 27158893
[TBL] [Abstract][Full Text] [Related]
8. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
[TBL] [Abstract][Full Text] [Related]
9. Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking.
Walker N; Howe C; Bullen C; McRobbie H; Glover M; Parag V; Williman J; Veale R; Nosa V; Barnes J
BMC Public Health; 2011 Nov; 11():880. PubMed ID: 22104038
[TBL] [Abstract][Full Text] [Related]
10. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
[TBL] [Abstract][Full Text] [Related]
11. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2007 Jan; (1):CD006103. PubMed ID: 17253581
[TBL] [Abstract][Full Text] [Related]
12. Cytisine Versus Varenicline for Smoking Cessation in a Primary Care Setting: A Randomized Non-inferiority Trial.
Oreskovic T; Percac-Lima S; Ashburner JM; Tiljak H; Rifel J; Klemenc Ketiš Z; Oreskovic S
Nicotine Tob Res; 2023 Aug; 25(9):1547-1555. PubMed ID: 37291049
[TBL] [Abstract][Full Text] [Related]
13. Cytisine versus nicotine for smoking cessation.
Walker N; Howe C; Glover M; McRobbie H; Barnes J; Nosa V; Parag V; Bassett B; Bullen C
N Engl J Med; 2014 Dec; 371(25):2353-62. PubMed ID: 25517706
[TBL] [Abstract][Full Text] [Related]
14. Cytisine versus varenicline for smoking cessation in New Zealand indigenous Māori: a randomized controlled trial.
Walker N; Smith B; Barnes J; Verbiest M; Parag V; Pokhrel S; Wharakura MK; Lees T; Cubillos Gutierrez H; Jones B; Bullen C
Addiction; 2021 Oct; 116(10):2847-2858. PubMed ID: 33761149
[TBL] [Abstract][Full Text] [Related]
15. Cytisine for smoking cessation: a research agenda.
Etter JF; Lukas RJ; Benowitz NL; West R; Dresler CM
Drug Alcohol Depend; 2008 Jan; 92(1-3):3-8. PubMed ID: 17825502
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of nicotine salt vapes, cytisine, and a combination of these products, for smoking cessation in New Zealand: protocol for a three-arm, pragmatic, community-based randomised controlled trial.
Walker N; Calder A; Barnes J; Laking G; Parag V; Bullen C
BMC Public Health; 2023 Sep; 23(1):1760. PubMed ID: 37697327
[TBL] [Abstract][Full Text] [Related]
17. An uncontrolled trial of cytisine (Tabex) for smoking cessation.
Zatonski W; Cedzynska M; Tutka P; West R
Tob Control; 2006 Dec; 15(6):481-4. PubMed ID: 17130378
[TBL] [Abstract][Full Text] [Related]
18. Varenicline versus placebo for waterpipe smoking cessation: a double-blind randomized controlled trial.
Dogar O; Zahid R; Mansoor S; Kanaan M; Ahluwalia JS; Jawad M; Siddiqi K
Addiction; 2018 Dec; 113(12):2290-2299. PubMed ID: 30187978
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness, safety and cost-effectiveness of vaporized nicotine products versus nicotine replacement therapy for tobacco smoking cessation in a low-socioeconomic status Australian population: a study protocol for a randomized controlled trial.
Howard BC; McRobbie H; Petrie D; Barker D; Mendelsohn C; Anderson J; Borland R; Naughton F; Tutka P; Zwar N; Boland VC; Aiken A; Shakeshaft A; Gartner C; Richmond RL; Hall W; Mattick RP; Farrell M; Courtney RJ
Trials; 2022 Sep; 23(1):777. PubMed ID: 36104702
[TBL] [Abstract][Full Text] [Related]
20. Cytisine for smoking cessation: A systematic review and meta-analysis.
Ofori S; Lu C; Olasupo OO; Dennis BB; Fairbairn N; Devereaux PJ; Mbuagbaw L
Drug Alcohol Depend; 2023 Oct; 251():110936. PubMed ID: 37678096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
